AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OPTHEA LTD

0.600

+0.000

Volume:- -

Turnover:- -

Market Cap:738.77M

PE:-1.47

High:0.600

Open:0.600

Low:0.600

Close:0.600

Loading ...

Overview Company News Filings

Hearts and Minds Investments Portfolio Falls Nearly 9% in March

MT Newswires Live

Thursday’s HotCopper Trends: Sayona merger, Opthea slashes jobs | April 10, 2025

The Market Herald

BRIEF-Opthea Says Reducing Workforce By 65%

Opthea Cuts 65% Staff, Terminates Drug Trials

MT Newswires Live

Opthea, with shares still suspended, cuts workforce by 65% after drug trials cancelled

The Market Herald

Opthea Ltd - Reducing Its Workforce by Approximately 65%

THOMSON REUTERS

Opthea - Material Uncertainty on Co's Ability to Continue as Going Concern

THOMSON REUTERS

Opthea Ltd - One-off Costs Associated With Reduction in Force Will Be Approximately US$4.5M

THOMSON REUTERS

Wednesday’s HotCopper Trends: MinRes down on iron ore slump, Regal Partners’ $540M funds loss | April 9, 2025

The Market Herald

LICs typically have healthy dividend coverage

Broker laments 'catastrophic negative surprise' that highlights the risks with these types of ASX shares

This ASX share potentially 'has no value from here', says broker

Hearts and Minds Investments Writes Down Opthea Holding to Zero

MT Newswires Live

Market Chatter: Regal Takes Responsibility for Opthea Investment Losses

MT Newswires Live

Opthea Ends Development of Sozinibercept in Wet AMD

Opthea Terminates Sozinibercept Development After Failed Phase 3 Trials

MT Newswires Live

BRIEF-Opthea Ltd Announces Decision To Discontinue Wet AMD Trials

Opthea Announces Decision to Discontinue Wet Amd Trials

THOMSON REUTERS

Opthea Announces Decision to Discontinue Wet AMD Trials

Opthea Ltd - Estimates Will Have Unaudited Cash and Cash Equivalents of US$100M at End of March 2025

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/OPT.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OPT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPT.AU\",,,,,undefined,":{"symbol":"OPT.AU","market":"AU","secType":"STK","nameCN":"OPTHEA LTD","latestPrice":0.6,"timestamp":1745301600000,"preClose":0.6,"halted":3,"volume":0,"delay":0,"nameEN":"OPTHEA LTD","floatShares":786007538,"shares":1231287336,"eps":-0.40889158918005075,"marketStatus":"Halted","change":0,"latestTime":"04-22 16:00:00 AEST","open":0.6,"high":0.6,"low":0.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.40889158918005075,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.6,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPT.AU\",,,,,undefined,":{"symbol":"OPT.AU","floatShares":786007538,"roa":"-73.34%","roe":"-3383.08%","lyrEps":-0.536238,"shares":1231287336,"dividePrice":0,"high":0.6,"amplitude":0,"preClose":0.6,"low":0.6,"week52Low":0.335,"pbRate":"-2.82","psRate":"2276.36","week52High":1.165,"institutionHeld":0,"latestPrice":0.6,"eps":-0.40889158918005075,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.40889158918005075,"open":0.6,"prevYearClose":0.81,"prevWeekClose":0.6,"prevMonthClose":0.6,"prevQuarterClose":0.6,"fiveDayClose":0.6,"twentyDayClose":0.6,"sixtyDayClose":0.94},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OPT.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526524680","title":"Hearts and Minds Investments Portfolio Falls Nearly 9% in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2526524680","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526524680?lang=en_us&edition=fundamental","pubTime":"2025-04-11 08:19","pubTimestamp":1744330743,"startTime":"0","endTime":"0","summary":"Hearts and Minds Investments'  portfolio declined 8.9% in March, bigger than the MSCI World Index's 5.2% drop in the same month, according to a Friday filing with the Australian bourse.The decline occurred as equity markets faced volatility during the month amid uncertainties about US trade policies, the filing said.The investment company also saw the unsuccessful outcome of Opthea's  phase 3 clinical trials for its lead drug candidate, OPT-302. This prompted Hearts & Minds to write down its investment to zero.Before its trading suspension, Opthea represented around 2.4% of Hearts and Minds Investments' portfolio, per a Tuesday statement.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","OPT.AU","HM1.AU","OPT","BK4139","BK7508"],"gpt_icon":0},{"id":"2526776643","title":"Thursday’s HotCopper Trends: Sayona merger, Opthea slashes jobs | April 10, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2526776643","media":"The Market Herald","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526776643?lang=en_us&edition=fundamental","pubTime":"2025-04-10 11:04","pubTimestamp":1744254240,"startTime":"0","endTime":"0","summary":"The ASX has been up, charging 4.7% higher at around 7,720 points today.Sayona Mining  has been among the most watched on HotCopper forums on news it has merged with NASDAQ-listed Piedmont Lithium. The name of the company will be changed to Elevra Lithium once the deal closes.Sayona Mining has been 1.6 cents in early afternoon trades.BOSS Energy  has also been trending on the forums after presenting at the Resources Rising Stars conference today. The company shared actual production and sales results for Q3 FY25.Finally, Opthea  shared a corporate update after the termination of its COAST Phase 3 clinical trials. In light of the negative trial results, the Board has decided to reduce costs and has slashed 65% of the workforce.Join the discussion: See what’s trending right now on HotCopper, Australia’s largest stock forum, and be part of the conversations that move the markets.The material provided in this article is for information only and should not be treated as investment advice. Vi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/thursdays-hotcopper-trends-sayona-merger-opthea-slashes-jobs-april-10-2025-2025-04-10/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BOE.AU","BK4139","BK7095","SYA.AU","OPT","OPT.AU","BK7067","BK7083","BK7508","BK7504"],"gpt_icon":0},{"id":"2526322798","title":"BRIEF-Opthea Says Reducing Workforce By 65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526322798","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526322798?lang=en_us&edition=fundamental","pubTime":"2025-04-10 09:31","pubTimestamp":1744248712,"startTime":"0","endTime":"0","summary":"BRIEF-Opthea Says Reducing Workforce By 65%April 10  - Opthea Ltd OPT.AX:REDUCING ITS WORKFORCE BY APPROXIMATELY 65%ONE-OFF COSTS ASSOCIATED WITH REDUCTION IN FORCE WILL BE APPROXIMATELY US$4.5MMATERIAL UNCERTAINTY ON CO'S ABILITY TO CONTINUE AS GOING CONCERNFurther company coverage: OPT.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QN1YR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","OPT.AU","BK7067"],"gpt_icon":0},{"id":"2526324926","title":"Opthea Cuts 65% Staff, Terminates Drug Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2526324926","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526324926?lang=en_us&edition=fundamental","pubTime":"2025-04-10 09:16","pubTimestamp":1744247818,"startTime":"0","endTime":"0","summary":"Opthea  has terminated phase three clinical trials for two of its drug candidates following negative results, according to a Thursday Australian bourse filing.The company will be reducing its workforce by about 65% to cut costs while retaining a limited number of employees to ensure compliant termination of clinical trial activities and oversee administrative operations, the filing added.The company expects the workforce reduction to take effect from May 1 with one-off costs of about $4.5 million, resulting reduction in monthly employee costs of $1 million.The company sees unaudited cash and cash equivalents of $100 million at the end of March.The company said its ability to continue as a going concern remains materially uncertain.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","OPT.AU","OPT","BK4139"],"gpt_icon":0},{"id":"2526129322","title":"Opthea, with shares still suspended, cuts workforce by 65% after drug trials cancelled","url":"https://stock-news.laohu8.com/highlight/detail?id=2526129322","media":"The Market Herald","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526129322?lang=en_us&edition=fundamental","pubTime":"2025-04-10 09:07","pubTimestamp":1744247220,"startTime":"0","endTime":"0","summary":"Troubled biotech stock Opthea , still in the process of crisis talks with investors, has flagged a workforce reduction of -65%.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.This comes not long after Opthea’s flagship Phase 3 trial treating age-related vision loss came up empty-handed because its drug of interest simply wasn’t proven to be effective.Those results prompted Opthea to abandon not one, but two trials; and now, what was a former favourite among HotCopper‘s myriad biotech watchers, is quickly becoming a letdown.Probably nobody is more aware of this than Opthea.“As previously disclosed, the company remains in active negotiations with its [keystone] investors… to explore possible options to deliver the best outcome for the company and its shareholders,” the company wrote.The material provided in this article is for information only and should not be treated as investment a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/opthea-with-shares-still-suspended-cuts-workforce-by-65-after-drug-trials-cancelled-2025-04-10/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["OPT.AU","BK7508","BK4139","BK7067","OPT"],"gpt_icon":0},{"id":"2526401613","title":"Opthea Ltd - Reducing Its Workforce by Approximately 65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526401613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526401613?lang=en_us&edition=fundamental","pubTime":"2025-04-10 07:21","pubTimestamp":1744240903,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN1YR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","OPT.AU","BK7067"],"gpt_icon":0},{"id":"2526340191","title":"Opthea - Material Uncertainty on Co's Ability to Continue as Going Concern","url":"https://stock-news.laohu8.com/highlight/detail?id=2526340191","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526340191?lang=en_us&edition=fundamental","pubTime":"2025-04-10 07:21","pubTimestamp":1744240903,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN1YR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","OPT.AU","BK7508"],"gpt_icon":0},{"id":"2526340164","title":"Opthea Ltd -  One-off Costs Associated With Reduction in Force Will Be Approximately US$4.5M","url":"https://stock-news.laohu8.com/highlight/detail?id=2526340164","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526340164?lang=en_us&edition=fundamental","pubTime":"2025-04-10 07:21","pubTimestamp":1744240903,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN1YR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OPT.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2526068818","title":"Wednesday’s HotCopper Trends: MinRes down on iron ore slump, Regal Partners’ $540M funds loss | April 9, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2526068818","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526068818?lang=en_us&edition=fundamental","pubTime":"2025-04-09 11:07","pubTimestamp":1744168020,"startTime":"0","endTime":"0","summary":"The ASX 200 has been down nearly 1% to 7,438 points after the U.S. government announced late last night it’d be pushing tariffs against China to 104%.Mineral Resources  has been among the most watched companies on the HotCopper forum. It’s had a very bad day in trade, slumping to 11.9% on no news. However, it should be noted one of its focal commodities – iron ore – has also plunged to US$94.90 today on the Singapore exchange – the lowest since September.Regal Partners  has also been trending; it dropped by 6.6% after announcing the loss of $540 million across funds in the March quarter following a writedown to zero of an equity investment in biotech company Opthea .And, Insurance Australia Group  has had a slightly better performance on the market, up 2.3% despite reporting no timely news. IAG was trading at $7.50.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consul","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/wednesdays-hotcopper-trends-minres-down-on-iron-ore-slump-regal-partners-540m-funds-loss-april-9-2025-2025-04-09/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7504","BK7034","IAG.AU","BK7508","MIN.AU","OPT.AU","BK7067","BK7507","BK7062","RPL.AU","BK7095"],"gpt_icon":0},{"id":"2525851037","title":"LICs typically have healthy dividend coverage","url":"https://stock-news.laohu8.com/highlight/detail?id=2525851037","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525851037?lang=en_us&edition=fundamental","pubTime":"2025-04-07 09:45","pubTimestamp":1743990314,"startTime":"0","endTime":"0","summary":"As we discussed in our outlook for 2025 in the newsletter published on 17 December 2025, the policies enacted by President Trump were always going to shape the markets for 2025. The President’s policies on tariffs during the week took everybody by surprise with the extent of the sweeping tariffs greater than the market expected, which triggered a material sell off in markets globally. The extent of the sell off is unknown at this time, however we expect market volatility to continue as a result of the greater than expected economic impact that the tariffs are expected to have.LICs generally have a healthy level of dividend coverage which, depending on the dividend policy, will provide the ability to support dividends through a period of market weakness. However, this is not the case for all LICs which may result in dividend volatility for some investors. LIC dividends are at the discretion of the boards with market conditions potentially impacting dividends declared.We were expecting a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/lics-typically-have-healthy-dividend-coverage","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/lics-typically-have-healthy-dividend-coverage","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK4086","SEC.AU","LU0274383776.USD","BK7129","LU0757428866.USD","BK7095","MOT.AU","MXT.AU","WMX.AU","BK7508","PE1.AU","MCH","BK7067","BCI","LU0053671581.USD","PIC.AU","MCH.AU","OPT.AU","BCI.AU","LU1815336091.USD","SSD"],"gpt_icon":0},{"id":"2525222758","title":"Broker laments 'catastrophic negative surprise' that highlights the risks with these types of ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2525222758","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525222758?lang=en_us&edition=fundamental","pubTime":"2025-04-05 04:00","pubTimestamp":1743796800,"startTime":"0","endTime":"0","summary":"ASX share Opthea Limited (ASX: OPT)remains suspended from trading as the biotechcompany works to avoid insolvency.  Opthea last traded at 60 cents per share.   Last week, we learned that Opthea has de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/05/broker-laments-catastrophic-negative-surprise-that-highlights-the-risks-with-these-types-of-asx-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["MSB.AU","BK7501","CSL.AU","BK7508","BK7067","OPT.AU","BK7511","OPT","BK4139","XJO.AU"],"gpt_icon":0},{"id":"2524227858","title":"This ASX share potentially 'has no value from here', says broker","url":"https://stock-news.laohu8.com/highlight/detail?id=2524227858","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524227858?lang=en_us&edition=fundamental","pubTime":"2025-04-04 12:55","pubTimestamp":1743742507,"startTime":"0","endTime":"0","summary":"The ASX biotech advised investors on 24 March that its Phase 3 COAST clinical trial of OPT-302 had failed to meet its primary endpoint.  The trial was assessing sozinibercept  combined with aflibercept to treat wet AMD. The failure of the trial raised serious financial concerns for Opthea. The company said it would review its obligations under its Development Funding Agreement  with key investors to decide the next steps.  What's the latest news with this ASX biotech share?Importantly, Opthea and its DFA investors have agreed that ceasing both trials does not constitute a 'termination event' under the DFA. This means Opthea does not","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/04/this-asx-share-potentially-has-no-value-from-here-says-broker/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU0642271901.SGD","OPT.AU","LU1242518931.SGD","LU1989764664.SGD","LU1951200564.SGD","BK4139","BK4141","BK4512","IE00BMPRXR70.SGD","BK7508","LU2264538146.SGD","LU0719512351.SGD","LU2360106780.USD","IE00B5949003.HKD","BK4585","BK4612","LU1316542783.SGD","LU1803068979.SGD","IE0009356076.USD","BK4588","LU1064131342.USD","BK4534","BK4605","BK4573","OPT","LU0198837287.USD","LU0823434740.USD","LU0823421333.USD","GFS","LU0823434583.USD","LU0056508442.USD","BK4529","BK4575","LU2458330243.SGD","LU2458330169.SGD","LU0979878070.USD","LU1951198990.SGD","LU2054465674.USD","LU0082616367.USD","LU1880398471.USD","BK4566","IE0004445239.USD","LU1303367103.USD","LU1852331112.SGD","LU0127658192.USD","LU0390134368.USD","LU1988902786.USD","BK7067","LU0109392836.USD"],"gpt_icon":1},{"id":"2524548879","title":"Hearts and Minds Investments Writes Down Opthea Holding to Zero","url":"https://stock-news.laohu8.com/highlight/detail?id=2524548879","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524548879?lang=en_us&edition=fundamental","pubTime":"2025-04-02 12:03","pubTimestamp":1743566613,"startTime":"0","endTime":"0","summary":"Hearts and Minds Investments  said its board decided to write down the value of its portfolio holding in Opthea  to zero, effective Monday, according to a Wednesday Australian bourse filing.The board had previously written down the value of the holding to AU$0.20 per share.The write-down will negatively impact the net asset value of the firm by around AU$0.034 per share, the filing said.This move comes after Opthea said that its second phase three trial of a treatment for an eye disease had failed.Hearts and Minds Investments' shares jumped past 1% in recent trading on Wednesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPT","BK7508","BK7067","HM1.AU","BK4139","OPT.AU"],"gpt_icon":0},{"id":"2524177853","title":"Market Chatter: Regal Takes Responsibility for Opthea Investment Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2524177853","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524177853?lang=en_us&edition=fundamental","pubTime":"2025-04-02 09:23","pubTimestamp":1743557031,"startTime":"0","endTime":"0","summary":"Regal Investment Fund  Chief Investment Officer Phil King has taken responsibility for the firm's losses stemming from its investment in Opthea , the Australian Financial Review reported Wednesday, citing a letter to investors.Opthea has said that its study of the combination of OPT-302 and aflibercept in patients with age-related macular degeneration failed to meet its primary endpoint, prompting it to terminate the study. It also added that there is \"significant\" doubt about its ability to continue as a going concern.Regal, which held a 30% stake in Opthea, has written down the investment to zero, acknowledging the blow to investor returns across several funds, the report said.The loss is expected to \"significantly\" affect the performance of Regal's long and short equity strategies for March, the report said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPT.AU","BK7508","OPT","RF1.AU","BK4139","BK7067"],"gpt_icon":0},{"id":"2523420469","title":"Opthea Ends Development of Sozinibercept in Wet AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2523420469","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523420469?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:37","pubTimestamp":1743428220,"startTime":"0","endTime":"0","summary":"Opthea is scrapping development of lead product candidate sozinibercept in wet age-related macular degeneration, or wet AMD, following the failure of another late-stage study.Opthea on Monday said its second Phase 3 study of sozinibercept in combination with aflibercept in wet AMD, an eye condition that causes blurred vision or reduced central vision, missed its primary endpoint of mean change in best corrected visual acuity.The clinical-stage biopharmaceutical company said it opted to accelerate the study readout following the similar Phase 3 study failure it reported last week.Opthea said it agreed with the investors in its development funding agreement to end development of sozinibercept in wet AMD, and that the move wouldn't constitute a termination event under the funding deal.However, the company warned once again that it might be required to pay amounts to the investors--which would have a material adverse effect on its solvency--and that there is material uncertainty about its ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU1803068979.SGD","LU2264538146.SGD","BK4139","LU0823421416.USD","LU0056508442.USD","LU0082616367.USD","LU2458330169.SGD","LU0889565833.HKD","LU0109392836.USD","LU0823421333.USD","BK4588","LU0198837287.USD","LU1951198990.SGD","LU0390134368.USD","LU0823434740.USD","BK4585","IE00BMPRXR70.SGD","LU0979878070.USD","LU1989764664.SGD","BK4529","BK4532","LU1064131342.USD","LU0823434583.USD","LU2458330243.SGD","GFS","BK4543","BK4605","LU0081259029.USD","OPT.AU","IE00B5949003.HKD","OPT","IE00BMPRXN33.USD","LU1316542783.SGD","IE0009356076.USD","BK4512","LU1988902786.USD","LU0127658192.USD","IE0004445239.USD","LU1242518857.USD","BK4573","BK4575","LU1880398554.USD","LU1923623000.USD","LU2054465674.USD","LU2098885051.SGD","LU2250418816.HKD","LU1242518931.SGD","BK7508"],"gpt_icon":1},{"id":"2523956912","title":"Opthea Terminates Sozinibercept Development After Failed Phase 3 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2523956912","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523956912?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:58","pubTimestamp":1743418697,"startTime":"0","endTime":"0","summary":"Opthea  said Monday that a phase 3 trial evaluating the efficacy and safety of 2 mg sozinibercept for wet age-related macular degeneration failed to meet its primary endpoint of improved visual acuity.The announcement is the second blow for the company as another phase 3 failed to meet its primary goal last week.Opthea and its Development Funding Agreement investors have agreed to immediately discontinue the development of sozinibercept for wet age-related macular degeneration, the company said.It added that the decision does not trigger a termination event under the  Development Funding Agreement, meaning no payment is required to be made by Opthea.The company said it continues discussions with  Development Funding Agreement investors to explore potential options for its future.Opthea estimates it will have $100 million in cash and cash equivalents by the end of March 2025 but faces uncertainty about its ability to continue as a going concern, the drug developer said.The ASX will susp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","OPT","OPT.AU","BK4139"],"gpt_icon":0},{"id":"2523993026","title":"BRIEF-Opthea Ltd Announces Decision To Discontinue Wet AMD Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2523993026","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523993026?lang=en_us&edition=fundamental","pubTime":"2025-03-31 16:34","pubTimestamp":1743410051,"startTime":"0","endTime":"0","summary":"BRIEF-Opthea Ltd Announces Decision To Discontinue Wet AMD TrialsMarch 31  - Opthea Ltd OPT.AX:ANNOUNCES DECISION TO DISCONTINUE WET AMD TRIALSCONTINUES ACTIVE DISCUSSIONS WITH DFA INVESTORSESTIMATES WILL HAVE UNAUDITED CASH AND CASH EQUIVALENTS OF US$100M AT END OF MARCH 2025THERE REMAINS MATERIAL UNCERTAINTY AS TO OPTHEA'S ABILITY TO CONTINUE AS A GOING CONCERNFurther company coverage: OPT.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC03L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPT.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2523951211","title":"Opthea Announces Decision to Discontinue Wet Amd Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2523951211","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523951211?lang=en_us&edition=fundamental","pubTime":"2025-03-31 12:01","pubTimestamp":1743393660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUABKBNM5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","OPT.AU"],"gpt_icon":0},{"id":"2523951735","title":"Opthea Announces Decision to Discontinue Wet AMD Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2523951735","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523951735?lang=en_us&edition=fundamental","pubTime":"2025-03-31 12:01","pubTimestamp":1743393660,"startTime":"0","endTime":"0","summary":"ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52. Opthea and DFA Investors agreed to terminate both COAST and ShORe trials. Opthea continues to consider impact of negative trial results under its Development Funding Agreement  and on the Company as a going concern. The global ShORe Phase 3 trial evaluated the efficacy and safety of intravitreally administered 2 mg sozinibercept every four or eight weeks in combination with 0.5 mg ranibizumab every four weeks, as per label, versus 0.5 mg ranibizumab monotherapy. The trial did not meet its primary endpoint of mean change in best corrected visual acuity  from baseline to week 52.“We are disappointed that COAST and ShORe did not demonstrate the improvements in vision with sozinibercept combination therapy compared to standard of care that we had hoped for,” said Frederic Guerard, PharmD, Chief Executive Officer of Opthea. “We are grateful to all patients, clinica","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/opthea-announces-decision-discontinue-wet-040100489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OPT.AU","IE00BMPRXN33.USD","IE00B5949003.HKD","LU1880398471.USD","LU0823421416.USD","LU1803068979.SGD","BK4605","BK4534","LU2250418816.HKD","LU0823434740.USD","BK4139","BK4573","IE00BMPRXR70.SGD","BK4566","LU1880398554.USD","LU1989764664.SGD","LU0823434583.USD","LU1988902786.USD","LU2098885051.SGD","LU2054465674.USD","LU2264538146.SGD","OPT","LU2458330169.SGD","LU1951198990.SGD","LU1852331112.SGD","LU0889565833.HKD","LU0642271901.SGD","GFS","BK4585","LU1242518857.USD","LU0081259029.USD","LU1951200564.SGD","LU2360106780.USD","LU0390134368.USD","BK4612","BK4554","LU0719512351.SGD","BK4529","BK4575","LU0082616367.USD","LU1303367103.USD","BK4614","LU0127658192.USD","LU0979878070.USD","BK4512","BK4141","LU1923623000.USD","LU1316542783.SGD","LU1064131342.USD","IE0004445239.USD"],"gpt_icon":1},{"id":"2523932385","title":"Opthea Ltd - Estimates Will Have Unaudited Cash and Cash Equivalents of US$100M at End of March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2523932385","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523932385?lang=en_us&edition=fundamental","pubTime":"2025-03-31 09:42","pubTimestamp":1743385329,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC03L:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","OPT.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":77,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OPT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OPT.AU\",market:\"AU\",,,undefined,":[]}}